Vericel (NASDAQ:VCEL) Sees Unusually-High Trading Volume

Shares of Vericel Corp (NASDAQ:VCEL) saw an uptick in trading volume on Monday . 710,426 shares were traded during trading, an increase of 29% from the previous session’s volume of 550,490 shares.The stock last traded at $18.94 and had previously closed at $18.66.

VCEL has been the topic of a number of analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Vericel in a research note on Tuesday, November 5th. BidaskClub raised shares of Vericel from a “hold” rating to a “buy” rating in a report on Tuesday, October 29th. HC Wainwright began coverage on shares of Vericel in a research report on Wednesday, October 9th. They set a “buy” rating and a $19.00 price target on the stock. BTIG Research set a $24.00 price objective on shares of Vericel and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Zacks Investment Research reissued a “buy” rating and issued a $16.00 price objective on shares of Vericel in a research note on Saturday, October 12th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Vericel has an average rating of “Buy” and a consensus target price of $21.78.

The firm has a 50-day moving average of $17.39 and a two-hundred day moving average of $17.04. The firm has a market capitalization of $836.15 million, a P/E ratio of -133.14 and a beta of 2.72. The company has a current ratio of 6.93, a quick ratio of 6.48 and a debt-to-equity ratio of 0.26.

Vericel (NASDAQ:VCEL) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.09. Vericel had a positive return on equity of 3.66% and a negative net margin of 12.68%. The firm had revenue of $30.50 million during the quarter, compared to the consensus estimate of $26.84 million. During the same quarter in the previous year, the firm earned ($0.02) earnings per share. The business’s quarterly revenue was up 35.6% on a year-over-year basis. On average, sell-side analysts anticipate that Vericel Corp will post 0.16 EPS for the current fiscal year.

In other Vericel news, COO Michael Halpin sold 15,047 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $18.53, for a total value of $278,820.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Dominick Colangelo sold 58,125 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $14.88, for a total value of $864,900.00. The disclosure for this sale can be found here. Insiders own 4.50% of the company’s stock.

Several hedge funds have recently made changes to their positions in VCEL. Royal Bank of Canada lifted its holdings in shares of Vericel by 665.8% during the second quarter. Royal Bank of Canada now owns 1,547 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,345 shares during the period. Advisor Group Inc. grew its position in shares of Vericel by 152.1% during the 2nd quarter. Advisor Group Inc. now owns 2,652 shares of the biotechnology company’s stock worth $50,000 after buying an additional 1,600 shares during the period. Advisory Services Network LLC increased its stake in shares of Vericel by 100.0% in the 2nd quarter. Advisory Services Network LLC now owns 3,000 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,500 shares in the last quarter. Hussman Strategic Advisors Inc. bought a new stake in shares of Vericel in the 3rd quarter valued at $61,000. Finally, Aperio Group LLC acquired a new position in shares of Vericel during the 2nd quarter valued at $67,000. 86.86% of the stock is currently owned by hedge funds and other institutional investors.

Vericel Company Profile (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Further Reading: Economic Reports

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit